The effectiveness of a single respiratory syncytial virus (RSV) vaccine dose declined among older adults, potentially suggesting the need for booster shots among this demographic. That is according to ...

Respiratory syncytial virus (RSV) is a common germ that can settle into your lungs and airways. It's the top cause of upper respiratory infection in babies and toddlers, but anyone can get it. While ...

Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...

Cold and flu season typically happen during the fall and winter. Though it comes around every year, there's still a lot of ...

Thursday, Pfizer Inc (NYSE:PFE) announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the ...

Correlation Between Patient-reported and Clinician-assessed RSV Symptoms and Case Definition to Capture Moderate-to-Severe RSV Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase ...

This year, emergency departments nationwide are seeing an unusually early surge in very young and elderly patients with respiratory distress, often caused by respiratory syncytial virus or RSV. We ...

While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...

Belgian scientists from VIB and Ghent University (UGent), together with Danish collaborators, have uncovered compelling ...

Background Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections (ALRI) among under-5 ...